OPEN Health, a portfolio company of Amulet Capital Partners, has acquired Spirit Medical Communications
OPEN Health is a multi-disciplinary pharmaceutical communications and market access group. They operate across three core business areas: medical communications; patient and brand communications; and value, informatics and evidence. OPEN Health was formed in 2011 and works across a broad therapeutic range with a strong focus on oncology, rare diseases and specialist medicines. Amulet invested in the platform in 2018 to further accelerate its service offering and scale. The acquisition of Spirit Medical Communications fits into that growth plan in enhancing the OPEN Health communication offering and its presence across the UK and Europe.
Spirit Medical Communications was founded in 2006 and focuses on providing medical communications services, supporting global pharmaceutical companies in developing life-changing medicines.
Lincoln acted as the exclusive financial advisor for OPEN Health and Amulet, working closely with the shareholders and management throughout the process. This included providing strategic advisory expertise at critical moments during the competitive phase of the process. Terms of the transaction are not disclosed.
James West, Director in Lincoln’s Healthcare Group, commented, “Amulet has been an exceptional partner for OPEN Health since investing in the platform in 2018. The acquisition of Spirit Medical Communications into the OPEN Health group allows a deeper capability into medical writing and boosts their UK presence. It was a pleasure to work with OPEN Health and Amulet in ensuring success in this transaction.”
We chose to appoint Lincoln to advise us on this important transaction due to the healthcare group’s deep sector knowledge and reputation as a leader in outsourced pharmaceutical M&A advisory. Lincoln provided key guidance which gave OPEN Health a competitive edge in the process, ultimately leading to a successful outcome.
Meet our Senior Team
View More Transactions in Healthcare
Lincoln International advised Proclinic Group, a portfolio company of Miura Partners, on the acquisition of Meditrans
Lincoln International advised Frazier Lifesciences Acquisition Corporation on merger with NewAmsterdam Pharma Holding
Lincoln International advised Pfingsten Partners on the sale of Full Spectrum Group to CBRE Group
Lincoln International advised Rarebreed, a portfolio company of Trilantic Capital Partners and Halle Capital Management, on receiving significant investment from Revelstoke Capital Partners
Lincoln International advised Corus a portfolio company of Careventures and Quadrum Capital on the refinancing and acquisition of Nordentic
Any information or testimonials contained in this post may not be representative of the experience of other clients and is no guarantee of future performance or success.